
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)12543-1
10.1016/j.heliyon.2024.e36512
e36512
Review Article
Regulatory T lymphocytes as a treatment method for rheumatoid arthritis – Superiority of allogeneic to autologous cells
Chmiel Joanna jchmiel@uck.gda.pl
ab⁎
Stasiak Mariusz ab
Skrzypkowska Maria c
Samson Lucjan ab
Łuczkiewicz Piotr b
Trzonkowski Piotr c
a University Clinical Centre in Gdańsk, Second Clinic of Orthopaedics and Kinetic Organ Traumatology, Poland
b Faculty of Medicine, Medical University of Gdańsk, Poland
c Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Poland
⁎ Corresponding author. University Clinical Centre in Gdańsk, Second Clinic of Orthopaedics and Kinetic Organ Traumatology, Dębinki 7, 80-952, Gdańsk, Poland. jchmiel@uck.gda.pl
30 8 2024
15 9 2024
30 8 2024
10 17 e3651216 2 2024
15 8 2024
16 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Cellular therapies utilizing regulatory T cells (Tregs) have flourished in the autoimmunity space as a new pillar of medicine. These cells have shown a great promise in the treatment of such devastating conditions as type 1 diabetes mellitus (T1DM), systemic lupus erythematosus (SLE) and graft versus host disease (GVHD). Novel treatment protocols, which utilize Tregs-mediated suppressive mechanisms, are based on the two main strategies: administration of immunomodulatory factors affecting Tregs or adoptive cell transfer (ACT). ACT involves extraction, in vitro expansion and subsequent administration of Tregs that could be either of autologous or allogeneic origin. Rheumatoid arthritis (RA) is another autoimmune candidate where this treatment approach is being considered. RA remains an especially challenging adversary since it is one of the most frequent and debilitating conditions among all autoaggressive disorders. Noteworthy, Tregs circulating in RA patients' blood have been proven defective and unable to suppress inflammation and joint destruction. With this knowledge, adoptive transfer of compromised autologous Tregs in the fledgling clinical trials involving RA patients should be reconsidered. In this article we hypothesize that incorporation of healthy donor allogeneic Tregs may provide more lucid and beneficial results.

Highlights

• Adoptive transfer (ACT) of autologous Tregs helps to treat autoimmune diseases.

• Tregs become defective in the inflammatory conditions.

• ACT of allogeneic Tregs may become more beneficial than transfer of autologous cells.

• Creating an allogeneic immune cell bank system could offer advantages.

Keywords

Regulatory T cells (tregs)
Rheumatoid arthritis (RA)
Adoptive cell therapy (ACT)
==== Body
pmcAbbreviations

RA - Rheumatoid Arthritis

QUEST-RA - Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis

DMARDs – Disease-Modifying Antirheumatic Drugs

JAKi – Janus Kinase inhibitor

Tregs – Regulatory T lymphocytes

T1DM - Type 1 Diabetes Mellitus

SLE – Systemic Lupus Erythematosus

GVHD – Graft versus Host Disease

ACT – Adoptive Cell Transfer/Therapy

CD – Cluster of Differentiation

IL-2 – Interleukin 2

Foxp3 – Forkhead box P3

tTregs – Thymus-derived Regulatory T lymphocytes

pTregs – Peripherally-derived Regulatory T lymphocytes

iTregs – Induced Regulatory T lymphocytes

TGF-β – Transforming Growth Factor beta

ACP - Antigen Presenting Cell

TNF-α – Tumour Necrosis Factor alpha

PB – Peripheral Blood

SF – Synovial Fluid

OA – Osteoarthritis

Ab – Antibody

IFN-γ – Interferon gamma

Tconv - Conventional T cells

MSC – Mesenchymal Stem Cell

atRa - all-trans Retinoic Acid

TCR – T cell Receptor

MHC – Major Histocompatibility Complex

CAR – Chimeric Antigen Receptor

CRISPR - Clustered Regularly Interspaced Short Palindromic Repeats

DAS28 - Disease Activity Score

CDAI - Clinical Disease Activity Index

ACR - American College of Rheumatology

EULAR - European League Against Rheumatism

Teffs – T effector cells

QOL – Quality of Life

HLA – Human Leukocyte Antigen

UCB – Umbilical Cord Blood

ARDS – Acute Respiratory Distress Syndrome

GMP – Good Manufacturing Practice

HSCT – Hematopoietic Stem Cell Transplantation

1 Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial inflammation, leading to cartilage damage, bone erosion and, ultimately, severe joint destruction. Autoreactivity and dysregulation of self-tolerance are thought to be responsible for the disease onset. RA is one of the main causes of permanent work disability, associated with many social consequences [1]. Between January 2005 and October 2006, the QUEST-RA (Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis) project was conducted to achieve quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. With 4363 included participants, this international multi-centre cross-sectional database provided a thorough overview of clinical status and treatments of patients with RA. Data on demographic, disease and treatment-related variables were collected and analyzed using descriptive statistics, enriching our knowledge on RA specific demographic characteristics. The QUEST-RA database has continued to grow and in June 2009 included over 8000 patients from 86 clinics in 32 countries. Based on collected data, the statistcal analysis was performed, showing that work disability rates remain high among people with RA during this millennium. More than one third (37 %) of participants reported subsequent work disability because of RA [2].

Current therapies: conventional synthetic DMARDs, targeted synthetic DMARDs (JAK inhibitors) and biological DMARDs can induce remission in approximately 70 % of the patients, however, remaining 30 % experience incurable and extremely debilitating affliction [3,4]. Nowadays, all efforts are given to identify new therapeutic approaches, especially those focused on immune homeostasis [5,6].

Regulatory T lymphocytes (Tregs) are a vital part of the adaptive immune system, responsible for preventing excessive inflammatory responses and maintaining immune balance. They are a specialized subpopulation of T helper cells, essential for inhibiting pathological reactions towards self-antigen. Given their unique ability to control aberrant autoreactive responses, there has been a significant interest in targeting Tregs therapeutically [7]. The pivotal role of Tregs in the maintenance of immune balance gave rise to a number of studies on their physiology and therapeutic potential [8]. Currently, regulatory T cell-based therapies are way past the in vitro phase, demonstrated in murine models. They've entered the clinical phase and some promising results have been reported repeatedly. Over the years, a lot of data has been collected, showing a great efficacy of Treg-based treatment approaches, not only in autoimmune diseases but also in GVHD – one of the biggest challenges to overcome in bone marrow transplantation [9,10].

As for RA, the size of its clinical data repository remains limited when compared to T1DM or GVHD, which are the diseases that have drawn researchers' attention from the very beginning of the Treg-based therapies era. Nevertheless, in several completed trials, Tregs have been proven useful in the management of RA, helping to overcome impaired functions and reduced frequencies of factors responsible for maintaining immune balance. The most promising Treg-based treatment protocol seems to be the one involving adoptive transfer of in vitro expanded Tregs [11]. Adoptive T cell therapy (ACT) used in autoimmunity usually utilizes polyclonal autologous lymphocytes, extracted and isolated from the peripheral blood of the treated subject. Although peripheral blood of healthy individual usually provides a sufficient amount of Tregs, they present a terminally differentiated memory phenotype, which reduces not only the expansion capacity, but also the likelihood of successful engraftment and survival [12]. This situation changes in autoimmune conditions, such as RA, in which we observe Tregs reduced frequencies and impaired functions. Moreover, different reports have shown that high plasticity of Tregs makes them particularly susceptible to inflammatory signals [13]. As the result, their regulatory and anti-inflammatory profile becomes defective. This causes inability to control cytokine-activated T cell functions and results in autoimmune-mediated damage to the healthy tissue. While Tregs protect body against autoaggression in healthy individuals, under autoimmune conditions their immunosuppressive properties become insufficient and even contribute to exacerbation of the disease [14,15]. This unfortunate phenomenon seems to be one of the culprit behind the inability to achieve a full therapeutic success of polyclonal autologous ACT [16,17].

We believe that changing the source of regulatory lymphocytes to a healthy donor could bring more certain and valuable conlusions and better understanding of the complex mechanisms behind the immune tolarance in RA. In this narrative review, we provide a basic background on the regulatory T lymphocytes and their role in the treatment of autoimmunity. We also hypothesize about a novel approach in the treatment of RA, based on adoptive transfer of allogeneic regulatory T cells.

2 The aim of this narrative review

Our aim was to give a brief overview of studies focused on harnessing regulatory T lymphocytes as a new therapeutic approach to treat autoimmune and other immunological diseases, especially RA. In this review, we highlight both the advances and the challenges in this arena, such as Tregs declined stability under inflammatory conditions. We also summarize available data (as of June 2024) on the clinical trials involving in vivo Tregs enhancement in RA patients, as well as the first implementation of allogeneic Tregs in the treatment of different diseases.

3 Methods

A literature search was performed in October and November 2023 and updated in January 2024 in PubMed database. Additional abbreviated update was performed in June 2024. The database was searched using a combination of subject headings and free‐text terms in the title and abstract fields. Highlighted keywords for searching were: regulatory T cells, adoptive cell transfer, rheumatoid arthritis. We focused our interest on most recent papers (date of publication 2014 to present), especially extensive meta-analyses summarizing the data from the last two decades.

As for for the clinical trials research, database used was ClinicalTrials.gov. The date of our investigation was June 2024, with applied search criteria: Tregs; regulatory T lymphocytes; rheumatoid arthritis; allogeneic Tregs.

For practical purposes, the search strategies were limited to English language as no resources were available to translate papers in other languages.

4 Regulatory T lymphocytes

In 1995 Sakaguchi et al. reported a subset of T-helper lymphocytes (CD4+) that maintain immune homeostasis by suppressing proliferation of effector T-cells [18]. Those lymphocytes expressed characteristic receptor for IL-2 (CD25). Over the years, more data about Tregs properties has been collected, suggesting the important role of Foxp3 transcription factor, which defines Treg identity and function. The population of CD4(+)CD25(+)Foxp3(+)CD127(low/-) T lymphocytes is currently recognized as the major immunoregulatory subset since it has been the most thoroughly studied [19]. These cells are often called naturally-occurring Tregs (nTregs) and consist of two subgroups: thymus-derived Tregs (tTregs), produced by the thymus as a functionally distinct and mature population, and peripherally-derived Tregs (pTregs), generated extrathymically at peripheral sites under certain conditions.

Tregs differentiation from naïve CD4(+) cells is regulated by TCR signaling that commit precursors to a regulatory lineage. Tregs can also be induced from non-Tregs in vitro, e.g. by antigenic stimulation in the presence of TGF-β and IL-2 (induced Tregs (iTregs)) [20]. Interestingly, there is an increasing evidence that some CD8(+) T cells and B cells also show suppressive activity and have major impact on the immune homeostasis [21,22]. These findings confirm extremely complex nature of specific interactions between every cell in human immune system.

Naturally-occurring Treg lymphocytes present their regulatory effect via cell-cell contact or by producing anti-inflammatory cytokines [14] [Fig. 1]. As mentioned before, there have been some discoveries suggesting that under certain conditions, such as inflammatory environment, Tregs start to present pro-inflammatory features and fail in preventing autoaggression [23]. In 2014, a ground-breaking paper by Jeffrey Bluestone's group showed, using mice fate mapping analysis, that Tregs can start to produce IL-17 due to the down-regulation of Foxp3 gene transcriptional activity, triggered by autoimmune arthritis environment [24]. These IL-17 producing cells are particularly arthritogenic and capable of inducing a severe chondral damage. Tumour necrosis factor α (TNF-α), present in inflammed joints in high concentrations, is one of the cytokines that are responsible for the impaired Treg cells function [15,Table 1].Fig. 1 Mechanisms of Treg suppression.

CTLA-4 binds to CD80/CD86 on APC (Antigen Presenting Cell), inhibits antigen presentation and increases IDO (Indoleamine 2,3-dioxygenase) expression. IDO pathway induces T cells anergy and enhances Tregs function. PD-1 (Programmed Death Receptor 1) binds to its ligand on APC resulting in suppression of antigen-reactive activity of Teff (effector T lymphocyte).

TIGIT (T cell Immunoreceptor with Ig and ITIM domains) presented on Treg interacts with CD155 on dendritic cell and enhances the expression of IL-10, thus specifically suppresses proinflammatory Th1 and Th17 cells. Anti-inflammatory cytokines are also directly produced by Tregs. Exosomes (extracellular vesicles) secreted by Tregs contain many specific biological molecules, which are delivered to target cells and modulate immune responses by inhibiting T cell proliferation, inducing apoptosis and changing the cytokine expression profiles of target cells. Activated Tregs cells also utilize granzyme B and perforin to disrupt protective barrier of cell membrane and destroy integrity of the target cell. CD39/CD73 expressed on Treg degrade ATP into extracellular adenosine, which is implicated in the immunoregulatory activity by inhibiting antigen presentation by APCs. TRAIL/DR5 (TNF-Related Apoptosis-Inducing Ligand/Death Recptor 5) interaction activates caspase-8 to induce Teff apoptosis. ICOS (Inducible T-cell Co-Stimulator) signaling can mediate Tregs survival by fine-tuning the expression of multiple anti-apoptotic molecules and anti-inflammatory cytokines. CD25, also konown as IL-2 receptor (IL-2R), is expressed at high levels on the surface of Tregs. IL-2, though not produced by Tregs, is essential for their development. Tregs compete for IL-2 secreted by effector cells and prevent them from acquiring the sufficient amount for proliferation and activation.

Fig. 1

Table 1 Impairment of Tregs suppressive functions in inflammatory conditions.

Table 1Group of factors responsible for impaired Tregs suppressive function	Main representatives	Effect on Tregs	Reference	
Cytokines	IL-6
IL-1
IL-21
TNF-α*	Tregs proliferation ↓
Tregs apoptosis ↑
Teff resistance to suppression ↑
Foxp3 expression ↓	[[25], [26], [27], [28], [29]]	
Transcription factors&Signaling pathways	NF-κB
HIF-1
IRFs
AP-1
JAK/STAT
PI3K
TLR
Hhex
Foxp1
Eos
YAP
Notch	Tregs proliferation ↓
Tregs stability ↓
Foxp3 expression ↓
CD-25,CTLA-4 expression ↓
Foxp3 modification ↑	[[30], [31], [32], [33], [34]]	
Post-translational modification	Ubiquitination phosphorylation
O-GlcNAcylation acetylation
methylation	Foxp3 expression ↓
Foxp3 stability ↓
Dysregulation of Th17/Treg balance ↑	[25,[35], [36], [37]]	
miRNAs	miR-146a
miR-301a-3p
miR-142-3p
miR-23a-3p
miR-181a/b
miR-568
miR-17	Signaling pathways impairment ↑
Dysregulation of Th17/Treg balance ↑
Tregs apoptosis ↑
Tregs stability ↓
CTLA-4 expression ↓
Foxp3 expression ↓
Foxp3 modification ↑	[25,[38], [39], [40]]	
Proteins	PAR
Mst1/Mst2 mTOR	Signaling pathways impairment ↑
Foxp3 modification↑
Foxp3 expression ↓	[33,41,42]	
Cells	Th17
Th1
Nks	Tregs apoptosis ↑
Tregs proliferation ↓
Foxp3 expression ↓	[25,27,43,44]	
Abbrevations: IL – Interleukin; TNF-α – Tumor Necrosis Factor alpha; NF-κB - Nuclear Factor kappa-light-chain-enhancer of activated B cells; HIF-1 - Hypoxia-inducible Factor 1; IRFs - Interferon Regulatory Factors; AP-1 - Activator Protein-1; JAK/STAT - Janus Kinase/Signal Transduction and Transcription Activation; PI3K – Phosphatidylinositol 3-Kinase; TLR - Toll-like Receptors; Hhex - Homeobox protein Hhex; Foxp - Forkhead box P; Eos - transcription factor of the Ikaros family; YAP - Yes-associated Protein; PAR - Protease-activated Receptor; Mst1/Mst2 – Hippo kinases; mTOR - mammalian Target of Rapamycin kinase; Th – T helper lymphocytes; NKs – Natural Killer cells; CTLA-4 - Cytotoxic T lymphocyte–associated Protein 4.

* TNF-α has contradictory effects on the functions of Tregs [25].

4.1 Tregs in autoimmune diseases

Treg-mediated immunosuppression provides self-tolerance and any failure in that system leads to some kind of autoimmune disorder [45]. The pathological changes we observe as the result of immune imbalance may affect multiple systems and organs of the human body. Autoimmune diseases present a wide variation of symptoms: they may become chronic or acute; may present episodes of remission followed by aggressive relapses; the course of the disease may vary from mild to severe. Accordingly, their response to wide range of available treatment methods depends on many different factors and mechanisms, often not fully understood. Currently there are more than 80 types of autoimmune diseases described in the literature. They affect approximately 10 % of the global population [46]. Examples of such diseases include type 1 diabetes mellitus, multiple sclerosis, psoriasis and rheumatoid arthritis.

4.1.1 Tregs in RA

The prevalence of RA varies globally, with generally higher occurrence in the industrialized countries [47]. In the last years, RA was reported to be the most disabling disease, causing early departure from professional career path and enormous limitations in the social life area [2]. Immune regulation in RA is extremely complex and may be achieved through a direct cell-cell contact or paracrine signalling. Tregs mediate the downrgulation of antigen-presenting cells (APC) and also regulate the metabolism in effector T cells [8,48] [Fig. 1]. In the last two decades, there has been an explosion in the research describing the role of Tregs and their relevance in different autoimmune disorders, enriching our knowledge about the etiology and pathogenesis of autoimmunity.

It has been shown that Tregs are frequently found subpopulation in the peripheral blood (PB) and synovial fluid (SF) of RA patients - with significantly higher numbers in the latter [49]. In 2016, Morita et al. presented a meta-analysis of 31 studies, confirming that the proportion of Tregs, defined by both Foxp3 and CD25, was higher in SF than that in PB among RA patients [50]. However, enhanced presence of regulatory cells is clearly not sufficient to prevent autoimmunity. It is believed that suppressive function of Tregs is impaired partly because of pro-inflammatory cytokines (e.g.TNF-α) produced by synovium [51,52]. Unparalleled plasticity of Tregs is responsible for the loss of their anti-inflammatory phenotype in highly inflammatory environment of RA [53,54] [Table 1]. As compared to healthy individuals, the quantity of Tregs in the synovial fluid of RA patients may be higher, but this increased number does not compensate for functional impairment. Tregs affected by RA simply fail to suppress auto-reactive effector lymphocytes and start to contribute to the progression of the disease via number of mechanisms, such as Treg conversion to Th17 (Bluestone et al.) [24,55,56].

4.2 Tregs in non-autoimmune diseases

Tregs function is not limited to self-tolerance and autoimmunity. Over the years, several additional properties have been suggested [57]. Interestingly, emerging evidence suggest that regulatory T lymphocytes intervene in the inflammatory process that drive osteoarthritis (OA), considered for decades a simple degenerative disease. Some groups demonstrated that decreased Tregs responses may contribute in the pathogenesis of chondral damage in OA [58,59].

The role of Tregs have been also described in the regenerative process after stroke or myocardial infarction [[60], [61], [62]]. If so, it may imply similar regenerative activity around the joints.

Furthermore, it appears that the adaptive immunity during severe SARS-CoV-2 infection is dysregulated and the number of Tregs significantly decreased. At the same time, their functional suppressive potential seems to be elevated with high expression of molecular markers [63].

The undeniable role of regulatory T cells in the pathophysiology of cancer should also not be forgotten. In tumor-bearing individuals, Tregs compromise the response of immune system against tumour, and therefore accelerate the progression of cancer [[64], [65], [66]].

5 Treg-based therapies

To date, two main strategies have been developed in the field of Treg-based therapies: the administration of immunomodulatory factors enhancing the number or function of Tregs and ACT - adoptive transfer of in vitro expanded Treg lymphocytes. The first one rely on in vivo protocols, involving specific immulomodulatory agents targeting the key molecules of Tregs maintenance, thus improving Treg-mediated immune tolerance [67]. These therapies involve treatment with cytokines such as low-dose IL-2, IL-2/Anti-IL-2 Ab complex and IL-4, IL-12, IFN-γ– in murine models [10,48]. However, the most promising results were provided by clinical trials focused on adoptive immunotherapy [68].

ACT refers to the ex vivo manipulation of T cells and their subsequent reinfusion into patient. While numerous in-human trials have demonstrated that Tregs reduce the severity of autoimmune reactions, several impediments still remain, including Tregs variability and the practical need for their effective in vitro expansion techniques.

Many studies on the heterogeneity of regulatory T lymphocytes population revealed distinct subsets with different functions in the control of the immune homeostasis and induction of peripheral tolerance. All these Tregs subsets and their specific properties can be exploited to develop novel treatment methods [69].

As mentioned before, the number of Tregs circulating in the peripheral blood is significantly lower than that of other lymphocytes, making them challenging to extract and multiply. There have been also some controversies on the proper identification method for Tregs, which caused a lack of clarity in the firstly emerged studies [50]. Fortunately, consensus on coherent identity markers has been achieved, followed by introduction of specific protocols that allow in vitro expansion of Tregs in sufficient amount [[70], [71], [72]].

Efficient clinical-scale Treg product manufacturing involves three key steps – isolation, adequate ex vivo expansion, while maintaining regulatory properties, and quality assessment [73]. Currently, the CD4(+)CD25(+)Foxp3(+)CD127(low/-) phenotype is most commonly isolated from Tregs population through flow cytometry or immunobead-separation methods. Tregs can be further distinguished from resting conventional T cells (Tconv) by hypomethylation of Foxp3, which enables to recognize regulatory profile at the genetic level. Tregs are then activated in the presence of high levels of exogenous interleukin-2 (IL-2). Next step is cell proliferation stimulated by anti-CD3 and anti-CD28 (aCD3/28) beads [74].

Various approaches have been explored to enhance the proliferation, function and stability of Tregs, including modifying culture conditions or adding drugs, e.g. Treg + MSC (Mesenchymal Stem Cells) co-culture, rapamycin, IL-6 and TNF-α [75,76]. Given the low frequency of Tregs in human peripheral blood, a feasible approach is the in vitro generation of potent Tregs (iTregs) from non-Tregs, since they are much higher in numbers and relatively easy to isolate. iTreg cells can develop from naïve CD4(+)Foxp3(−)T cells upon TGF-β stimulation. However, unlike tTregs, iTregs are highly unstable, which is a significant obstacle to their use for adoptive immunotherapy [77]. Interestingly, all-trans retinoic acid (atRA), a vitamin A metabolite, has been proven essential in regulation of a wide range of biological processes, including the in vitro enhancement of Tregs function and stability. This development has become especially useful in the manufacturing of both nTregs and iTregs for adoptive transfer purposeses [78].

Most Tregs manufacturing methods have been developed and validated based on autologous polyclonal Treg products. Moreover, most clinical trials have also utilized only polyclonal Treg cells populations, acquired from the treated subject and subsequently expanded in vitro. However, evidence from pre-clinical studies has clearly shown that antigen-specific Treg-based ACT is vastly superior to polyclonal cell-based [79]. The most basic method to obtain antigen-specific product includes antigen-stimulated Tregs expansion. This approach is mainly used in transplantation, to prevent graft rejection, and involves the use of APCs (Antigen Presenting Cells) from the graft donor to specifically stimulate alloreactive Tregs from the recipient. However, the implementation of this method in autoimmunity is limited due to the lack of knowledge of patient-specific TCRs (T cell receptors), which recognize disease-relevant MHC (Major Histocompatibility Complex)-peptide complexes [9].

Accessibility and safety of polyclonal Tregs have made them more frequently used in ongoing and past clinical trials. Polyclonal Tregs used in ACT may be autologous, derived from peripheral blood of the treated subject (the most popular source), or allogeneic – isolated from a healthy donor. Umbilical cord blood (UCB) could also become the source of allogeneic regulatory cells [80].

5.1 Genetic engineering of Tregs

The emergence of advanced gene editing techniques has opened the door to new methods of Tregs modifications, creating therapeutics with improved specificity and function. These strategies include advanced generation of highly antigen-specific Tregs, based on viral transduction with CAR (Chimeric Antigen Receptor)- or engineered TCR-encoding vector, as well as genome editing, utilizing CRISPR technology [9,81,82]. Furthermore, transgenic overexpression of Foxp3 in antigen-specific conventional CD4(+) lymphocytes has become an appealing way to produce a larger source of suppressive cells for infusion, thus overcoming the challenges of low precursor frequency [83].

Without a doubt, technological advance in genomics and cell manufacturing has made such individualized therapies possible, unfortunately, they are still extremely expensive, thus difficult to incorporate on a larger scale. Furthermore, there are several risks associated with Tregs genetic engineering, such as off-target disruption of essential genes or carcinogenesis associated with viral transduction and gene editing. There is a pressing need for careful monitoring of ongoing clinical trials utilizing genetically engineered Tregs, to further characterize the long-term risks and ensure safety of such therapies [84,85].

5.2 Treg-based therapies in RA

Currently, synthetic conventional, synthetic targeted and biological DMARDs are widely used in clinical practice and allow to achieve remission in approximately two out of three patients [3,86,87]. In 2018 Chinese cross-sectional observational study, including a total of almost 2000 RA participants, showed that the proportions of patients who fulfilled remission criteria was only 1.75 %–10.90 % (depending on the method used to evaluate response to the treatment – DAS28, CDAI, ACR/EULAR). The results indicated that the rate of disease activity remission achieved by currently accepted treatment regimen is disappointing. Moreover, adverse effects of applied drugs occurred in approximately one in five patients [88]. New approach is needed for those who do not respond well to standard disease-modifying drugs. To meet expectations, researchers started to develop several new therapies, especially based on the autoimmune background of RA and Tregs unique properties.

First strategy – application of cytokines or specific antibodies that target Tregs that circulate in the body of the treated patient, provoking the increase in Tregs frequency or suppressive function – has been repeatedly proven effective. These studies have been successfully introduced into human trials more than 10 years ago and presented highly promising results in many autoimmune diseases, such as SLE, Sjögren syndrome, dermatomyositis [[89], [90], [91]]. Unfortunately, in RA population these cytokines have been used only very recently [Table 2]. One of the most interesting study was TRANSREG initiative that compared the biological and clinical responses to the administration of low doses IL-2 across 14 autoimmune and inflammatory pathologies over the course of 7 years (2014–2021). Primary endpoint assessed during TRANSREG study was the change in Tregs frequency, expressed as a percentage of total CD(+) count, after the induction period, compared with baseline. Secondary biological endpoints were changes in Tregs and other immune cells (e.g. CD3(+) T cells, CD4(+) T cells, CD8(+) T cells, CD19(+) B cells, NK cells/mm3) at specific periods of time, compared with baseline, and and ratio Tregs/Teffs in induction and maintenance period.Table 2 A brief summary of different approaches to in vivo Tregs enhancement in clinical trials involving RA patients. Database used for the research: ClinicalTrials.gov. Search criteria: Tregs; regulatory T lymphocytes; rheumatoid arthritis.

Table 2Therapeutic	Results	ClinicalTrials.gov ID	Reference	
Low-dose IL-2	Treg ↑	NCT01988506*	[93,94]	
CGI ↓	
Abatacept	Treg ↑	NCT02885818	[95]	
Breg ↑	
IL-10 ↑	
TGF-β ↑	
Th1 ↓	
Th17 ↓	
VAS ↓	
CRP ↓	
Low-dose hrIL-2 (+MTX
+Loxoprofen)	Tregs ↑	NCT02467504	[96]	
Th17 ↓	
ACR20 ↓	
CDAI ↓	
SDAI ↓	
Autologous BM-MSCs	Treg ↑	NCT03333681	[[97], [98], [99]]	
TGF-β ↑	
Th17 ↓	
IL-17A ↓	
DAS28-ESR ↓	
VAS ↓	
Ergocalciferol	Treg ↑	NCT04472481	[100]	
DAS28-CRP↓	
Abbreviations: hrIL-2 – human recombinant Interleukin 2; MTX – Methotrexate; BM-MSCs – Bone Marrow-derived Mesencymal Stem Cells; CGI - Clinical Global Impression; VAS – Visual Analogue Scale; CRP – C-reactive Protein; ACR – American College of Rheumatology 20 Response Criteria; CDAI - Clinical Disease Activity Index; SDAI - Simplified Disease Activity Index; DAS28 - Disease Activity Score; ESR - Erythrocyte Sedimentation Rate.

* Official title of NCT01988506 trial is „Induction of Regulatory T Cells by Low Dose IL-2 in Autoimmune and Inflammatory Diseases (TRANSREG)”. The aim of TRANSREG study was to compare biological and clinical responses to the administration of low doses IL-2 across 14 selected pathologies: Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis, Behcet's Disease, Granulomatosis with Polyangiitis, Takayasu's Disease, Crohn's Disease, Ulcerative Colitis, Autoimmune Hepatitis, Sclerosing Cholangitis, Sjögren Syndrome, Systemic Sclerosis and Idiopathic Thrombocytopenic Purpura.

Second strategy involves ACT, based mostly on polyclonal autologous lymphocytes (aside from GVHD patients – in this group allogeneic (donor) regulatory T cells are isolated and administered to the patient - recipient). This protocol has been efficiently implemented in number of clinical trials: completed (kidney transplant, T1DM) or ongoing (GVHD, SLE) [7,48,[101], [102], [103]]. There has been no officially registered clinical trial involving adoptive Tregs transfer in RA patients till the end of 2023. Interestingly, this situtation changed in March 2024, when Sonoma Biotherapeutics Inc. announced the recruitment of participants to Phase 1 Trial “Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis”. SBT777101 is an experimental biological treatment that consist of autologous CAR Treg lymphocytes [92].

6 Allogeneic Tregs ACT as a potential treatment method for RA

The great success of ACT in many autoimmune conditions (with T1DM being the leader in the field) made rheumatoid arthritis destined to become the next target. RA causes the impairment of all aspects of QOL (Quality of life) and inevitably leads to mental health, social, environmental and sexual dysfunctions [104]. With its extreme negative impact on society, it is only a matter of time before we witness widespread application of Treg-based ACT in clinical trials. It is crucial to carefully choosea suitable study design and methodology, reflectng the aims of the research, and reach only for the protocols based on the latest scientific findings, to provide the most transparent and critical evidence base for evaluating the safety and efficacy of new medical product. We are no longer grasping in the dark for answers in the mysterious world of autoimmune regulation. The last couple of years were extremely productive for researchers specialized in the therapeutic potential of Tregs. It seems unwise to copy some fundamentally false assumptions that lead to vague and questionable outcomes. With our current knowledge, we should re-consider the use of autologous Tregs ACT in the first in-man studies.

It has been repeatedly proven that Tregs in RA patients present different kinds and levels of intrinsic dysfunctions [105]. In these settings, expanding and adoptively transferring defective regulatory cells seems to be of limited benefit, unless we develop the way to stabilize their phenotype [106,107]. It is questionable how objectively valuable is the real potential of these cells, since we deal with only the defective ones. Taking into consideration that implementation of healthy donor allogeneic Tregs has been successful in the trials involving autoimmune and hematologic conditions, we suggest to incorporate the same protocol in RA research [Table 3].Table 3 Clinical trials involving allogeneic Tregs ACT as a treatment method of different diseases. Our investigation was conducted at the beginning of June 2024, using data from ClinicalTrials.gov registry, with „allogeneic Tregs” as the applied search criterion. The result showed 22 clinical trials; 8 of the studies turned out to be irrelevant to the topic of allogeneic Tregs ACT. Most of the remaining trials involved adoptive transfer of donor Tregs in the treatment of GVHD. Interestingly, 3 out of 5 actively recruiting studies are not focused on hematologic conditions.

Table 3ClinicalTrials.gov ID	Intervention/Treatment	Medical condition	Study Start – Study Completion	Study Type/Phase	Enrollment	Status	
NCT01795573	donor Tregs	GVHD	2014-10-29- 2020-08-14	Interventional
Phase 1	38	completed	
NCT06052436	allogeneic thyTregs	SIRS
ARDS
COVID-19	2023-06-27-2027-12-31 (estimated)	Interventional
Phase 1
Phase 2	24 (estimated)	recruiting	
NCT01937468	donor Tregs + IL-2	GVHD	2013-11-2024-12 (estimated)	Interventional
Phase 1	25	active, not recruiting	
NCT03977103	High dose irradiation conditioning + donor Tregs/Tcon + HSCT	Hematologic Malignancies	2014-02-2023-02-28	Interventional
Phase 2	80	unknown status	
NCT01903473	donor Tregs + IL-2
+ rapamycin	GVHD	2013-07-2022-09-12	Interventional
Phase 2	19	terminated (slow recruitment)	
NCT02749084	donor Tregs	GVHD	2016-08- 2022-06	Interventional
Phase 1
Phase 2	18	completed	
NCT05993611	Allogeneic CAR-Tregs	GVHD
Hematologic Malignancies	2024-06-17-2028-05-21 (estimated)	Interventional
Phase 1	27 (estimated)	recruiting	
NCT01660607	donor Tregs + Tcon	Hematologic Malignancies	2011-12-2023-12-20	Interventional
Phase 1
Phase 2	68	completed	
NCT04482699	allogeneic hybrid Treg/Th2 cell (RAPA-501-ALLO)	COVID-19-related ARDS	2020-12-30-2021-09-13	Interventional
Phase 1
Phase 2	1	terminated (change in eligible patient population)	
NCT05423691	allogeneic Tregs (CK0804)	Myelofibrosis	2022-12-27-2024-04-30 (estimated)	Interventional
Phase 1	24 (estimated)	recruiting	
NCT02385019	donor Tregs	GVHD	2015-03-2019-12	Interventional
Phase 1
Phase 2	22	unknown status	
NCT05695521	UCB-derived allogeneic Tregs (CK0803)	ALS	2023-04-03-2027-12 (estimated)	Interventional
Phase 1	66 (estimated)	recruiting	
NCT05088356	donor Tregs + HSCT +
Tcon	GVHD
Hematologic Malignancies	2021-09-07-2025-12 (estimated)	Interventional
Phase 1	40 (estimated)	recruiting	
NCT02423915	fucosylated UCB-derived
Tregs	GVHD	2015-07-30-2020-10-06	Interventional
Phase 1	5	completed	
Abbreviations: thyTregs – thymic regulatory T lymphocytes; Tcon – conventional T lymphocytes; HSCT - Hematopoietic Stem Cell Transplantation; GVHD – Graft versus Host Disease; SIRS – Systemic Inflammatory Response Syndrome; ARDS – Acute Respiratory Distress Syndrome; ALS - Amyotrophic Lateral Sclerosis.

Interestingly, allogeneic cells has already been used in the innovative therapies of RA – mesenchymal stem cells (MSCs) obtained from adipose tissue or umbilical cord have become one of the most promising approaches [108,109]. MSCs act as the immunosuppressive agents and, because of their important immunoprivileged properties, remain safe for allogeneic use. This results from MSCs having extremely low levels of major histocompatibility complex (MHC) class I and II molecules expression [110]. Somehow similar approach has been developed in our group where autologous Tregs were expanded in the presence of allogeneic mismatched MSC, which improved significantly the regulatory potential of Tregs [111]. Compared to mesenchymal, allogeneic Tregs ACT represent a challenge since administration of unmodified donor cells, unmatched in HLA complex, are likely to trigger sensitization or acute rejection by recipient immune system [83].

The obstacle of HLA mismatch could be overcomed by application of allogeneic Tregs derived from umbilical cord blood (UCB). The successful use of partially HLA-mismatched unrelated donor UCB as the source of hematopoietic stem cells has been reported as early as 1996 [112]. After the decades of studies, unrelated donor UCB has become the commonly acceptable alternative to HLA-matched bone marrow in the transplants among patients suffering from malignancies, BM failure, immunodeficiencies, etc [113]. Since UCB is easier to match than any other source of potentially therapeutic allogeneic cells, it has been widely and willingly used by researchers, providing some interesting findings, even concerning the recent pandemic [114]. Some newest reports show that the administration of allogeneic cord blood Tregs could be successfully used in the treatment of COVID-19 ARDS (Acute Respiratory Distress Syndrome) [115]. UCB is particularly alluring for clinical trials because it is the non-controversial and absolutely ethical source of stem cells collected post-birth, which prevents any political or religious issues. Obviously, cord blood has some limitations as the source of regulatory T lymphocytes, if they were to be used as a commonly accepted option for RA treatment. Cord-blood banking system is still growing, with The World Marrow Donor Association incharge, but faces many obstacles, such as financial issues or limited implementation of UCB banking in some countries [116].

7 Conclusions

Though still largely an experimental procedure, Treg-based adoptive cell therapy has recently become a clinical reality. Results from in-human trials are encouraging, but many questions remain to be addressed before this approach becomes routinely applicable to RA patients. We believe that the key to achieving satisfactory results of ACT in RA is implementation of the lymphocytes of allogeneic origin, not restricted by pathologic changes triggred by ongoing inflammatory processes.

The ideal situation in the distant future would be setting up a GMP(Good Manufacturing Practice)-compatible allogeneic cell banking system to cover large populations of patients – similar to hematopoietic stem cell transplantation (HSCT) strategies, exploited by physicians for decades [117]. The extensive use of immune cells from unrelated donors, optimally matched in MHC haplotypes, would offer many advantages over autologous cells, including improved cost-effectiveness, broader availability and higher quality of the product. Furthermore, allogeneic approach has the potential to provide a ready to use “off the shelf” immunotherapeutic, such that a single manufacturing run would allow multiple administration of the product. Likewise, by increasing the scale of production and creating a specific cell banking system, average cost per patient would decrease while the availability of therapeutic agent would increase [10,118]. The alternative for this ‘natural source’ of allogeneic Tregs might become Tregs with genetically engineered HLA that we are currently developing in our group. The idea is to create universal Treg donor lines by switching off HLA genes with either viral vectors or CRISPR technology [9,119].

Within the past decade, we have witnessed the transformative therapeutic potential of adoptive therapy for autoimmune conditions. However, at this point, we are still very far from clinical utilization of Tregs ACT on a bigger scale. At first we should focus on smaller trials, with carefully planned study design and methodology, to shed light on the exact mechanisms responsible for lymphocyte regulation in RA. This data would inevitably provide some further evidence of Tregs efficiency and safety in clinical practice. As long as we reach for defective autologous Tregs, proven abnormal or even pro-inflammatory, our results will not bring answers, only more pressing questions.

Data availability statement

Data included in this article and all supporting materials are referenced in article.

Data regarding clinical trials analyzed in this article are publicly available in ClinicalTrials.gov database.

Consent statement/Ethical approval

Not applicable.

Funding

This review received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

Joanna Chmiel: Writing – original draft, Investigation, Conceptualization. Mariusz Stasiak: Writing – review & editing, Investigation. Maria Skrzypkowska: Validation, Investigation. Lucjan Samson: Supervision, Resources. Piotr Łuczkiewicz: Supervision. Piotr Trzonkowski: Writing – review & editing, Project administration.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The work described in this article has not been published previously, it is not under consideration for publication elsewhere, its publication is approved by all the authors and tacitly or explicitly by the responsible authorities where the work was carried out, and if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.
==== Refs
References

1 Theis K.A. Roblin D.W. Helmick C.G. Luo R. Prevalence and causes of work disability among working-age U.S. adults, 2011-2013, NHIS Disabil Health J 11 1 2018 Jan 108 115 10.1016/j.dhjo.2017.04.010 Epub 2017 Apr 25. PMID: 28476583 28476583
2 Sokka T. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study Arthritis Res. Ther. 12 2 2010 R42 10.1186/ar2951 Epub 2010 Mar 12. PMID: 20226018; PMCID: PMC2888189
3 Smolen EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann. Rheum. Dis. 79 6 2020 Jun 685 699 10.1136/annrheumdis-2019-216655 Epub 2020 Jan 22. PMID: 31969328 31969328
4 Lewis M.J. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes Cell Rep. 28 9 2019 Aug 27 2455 2470.e5 10.1016/j.celrep.2019.07.091 PMID: 31461658; PMCID: PMC6718830 31461658
5 Liu S. Ma H. Zhang H. Deng C. Xin P. Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis Clin Immunol 230 2021 Sep 108793 10.1016/j.clim.2021.108793 Epub 2021 Jul 6. PMID: 34242749
6 Koga T. Kawakami A. Tsokos G.C. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis Clin Immunol 225 2021 Apr 108680 10.1016/j.clim.2021.108680 Epub 2021 Jan 23. PMID: 33493672
7 Goswami T.K. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - advances and challenges Hum Vaccin Immunother 18 1 2022 Dec 31 2035117 10.1080/21645515.2022.2035117 Epub 2022 Mar 3. PMID: 35240914; PMCID: PMC9009914
8 Okeke E.B. Uzonna J.E. The pivotal role of regulatory T cells in the regulation of innate immune cells Front. Immunol. 10 2019 Apr 9 680 10.3389/fimmu.2019.00680 PMID: 31024539; PMCID: PMC6465517 31024539
9 Raffin C. Vo L.T. Bluestone J.A. Treg cell-based therapies: challenges and perspectives Nat. Rev. Immunol. 20 3 2020 Mar 158 172 10.1038/s41577-019-0232-6 Epub 2019 Dec 6. PMID: 31811270; PMCID: PMC7814338 31811270
10 Selck C. Dominguez-Villar M. Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation Front. Immunol. 12 2021 May 14 661875 10.3389/fimmu.2021.661875 PMID: 34054826; PMCID: PMC8160309
11 Eberlein T.J. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2 J. Exp. Med. 156 August 1982 385 39 6980254
12 Bi Y. Kong R. Peng Y. Yu H. Zhou Z. Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: progress in type 1 diabetes Clin Immunol 255 2023 Oct 109716 10.1016/j.clim.2023.109716 Epub 2023 Aug 5. PMID: 37544491
13 Esparcia-Pinedo L. Lancho-Sánchez Á. Tsukalov I. Pacheco M.I. Martínez-Fleta P. Pérez-Miés B. Palacios-Calvo J. Sánchez-Madrid F. Martín-Gayo E. Alfranca A. T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity Clin Immunol 256 2023 Nov 109806 10.1016/j.clim.2023.109806 Epub 2023 Oct 11. PMID: 37827267
14 Shevyrev D. Tereshchenko V. Treg heterogeneity, function, and homeostasis Front. Immunol. 10 2020 Jan 14 3100 10.3389/fimmu.2019.03100 PMID: 31993063; PMCID: PMC6971100 31993063
15 Rajendeeran A. Tenbrock K. Regulatory T cell function in autoimmune disease J Transl Autoimmun 4 2021 Oct 30 100130 10.1016/j.jtauto.2021.100130 PMID: 35005594; PMCID: PMC8716637
16 Göschl L. Scheinecker C. Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies Semin. Immunopathol. 41 3 2019 May 301 314 10.1007/s00281-019-00741-8 Epub 2019 Apr 5. PMID: 30953162 30953162
17 Arellano B. Graber D.J. Sentman C.L. Regulatory T cell-based therapies for autoimmunity Discov. Med. 22 119 2016 Aug 73 80 PMID: 27585233; PMCID: PMC5573148 27585233
18 Sakaguchi S. Sakaguchi N. Asano M. Itoh M. Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases J. Immunol. 155 3 1995 Aug 1 1151 1164 PMID: 7636184 7636184
19 Miyara M. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor Immunity 30 6 2009 Jun 19 899 911 10.1016/j.immuni.2009.03.019 Epub 2009 May 21. PMID: 19464196 19464196
20 Shevach E.M. Thornton A.M. tTregs, pTregs, and iTregs: similarities and differences Immunol. Rev. 259 1 2014 May 88 102 10.1111/imr.12160 PMID: 24712461; PMCID: PMC3982187 24712461
21 Chekol Abebe E. Asmamaw Dejenie T. Mengie Ayele T. Dagnew Baye N. Agegnehu Teshome A. Tilahun Muche Z. The role of regulatory B cells in health and diseases: a systemic review J. Inflamm. Res. 14 2021 Jan 12 75 84 10.2147/JIR.S286426 PMID: 33469337; PMCID: PMC7811483 33469337
22 Liston A. Aloulou M. A fresh look at a neglected regulatory lineage: CD8+Foxp3+ Regulatory T cells Immunol. Lett. 247 2022 Jul 22 26 10.1016/j.imlet.2022.05.004 Epub 2022 May 21. PMID: 35609830 35609830
23 Moro-García M.A. Mayo J.C. Sainz R.M. Alonso-Arias R. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes Front. Immunol. 9 2018 Mar 1 339 10.3389/fimmu.2018.00339 PMID: 29545794; PMCID: PMC5839096 29545794
24 Komatsu N. Okamoto K. Sawa S. Nakashima T. Oh-hora M. Kodama T. Tanaka S. Bluestone J.A. Takayanagi H. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis Nat Med 20 1 2014 Jan 62 68 10.1038/nm.3432 Epub 2013 Dec 22. PMID: 24362934 24362934
25 Yang L. Wang G. Xia H. Molecular mechanism for impaired suppressive function of Tregs in autoimmune diseases: a summary of cell-intrinsic and cell-extrinsic factors J. Cell Mol. Med. 24 19 2020 Oct 11056 11063 10.1111/jcmm.15743 Epub 2020 Sep 2. PMID: 32881301; PMCID: PMC7576235 32881301
26 Guo H. Xun L. Zhang R. Hu F. Luan J. Lao K. Wang X. Gou X. Stability and inhibitory function of Treg cells under inflammatory conditions in vitro Exp. Ther. Med. 18 4 2019 Oct 2443 2450 10.3892/etm.2019.7873 Epub 2019 Aug 8. PMID: 31555356; PMCID: PMC6755276 31555356
27 Zhang J. Liu H. Chen Y. Liu H. Zhang S. Yin G. Xie Q. Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis Front. Immunol. 15 2024 Jan 23 1312919 10.3389/fimmu.2024.1312919 PMID: 38322264; PMCID: PMC10844451
28 Tortola L. Pawelski H. Sonar S.S. Ampenberger F. Kurrer M. Kopf M. IL-21 promotes allergic airway inflammation by driving apoptosis of FoxP3+ regulatory T cells J. Allergy Clin. Immunol. 143 6 2019 Jun 2178 2189.e5 10.1016/j.jaci.2018.11.047 Epub 2019 Jan 14. PMID: 30654048 30654048
29 Nie H. Zheng Y. Li R. Guo T.B. He D. Fang L. Liu X. Xiao L. Chen X. Wan B. Chin Y.E. Zhang J.Z. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis Nat Med 19 3 2013 Mar 322 328 10.1038/nm.3085 Epub 2013 Feb 10. PMID: 23396208 23396208
30 Balendran T. Lim K. Hamilton J.A. Achuthan A.A. Targeting transcription factors for therapeutic benefit in rheumatoid arthritis Front. Immunol. 14 2023 Jun 29 1196931 10.3389/fimmu.2023.1196931 PMID: 37457726; PMCID: PMC10339812
31 Simon L.S. Taylor P.C. Choy E.H. Sebba A. Quebe A. Knopp K.L. Porreca F. The Jak/STAT pathway: a focus on pain in rheumatoid arthritis Semin. Arthritis Rheum. 51 1 2021 Feb 278 284 10.1016/j.semarthrit.2020.10.008 Epub 2020 Dec 18. PMID: 33412435 33412435
32 Duan T. Du Y. Xing C. Wang H.Y. Wang R.F. Toll-like receptor signaling and its role in cell-mediated immunity Front. Immunol. 13 2022 Mar 3 812774 10.3389/fimmu.2022.812774 PMID: 35309296; PMCID: PMC8927970
33 Tomaszewicz M. Ronowska A. Zieliński M. Jankowska-Kulawy A. Trzonkowski P. T regulatory cells metabolism: the influence on functional properties and treatment potential Front. Immunol. 14 2023 Mar 3 1122063 10.3389/fimmu.2023.1122063 PMID: 37033990; PMCID: PMC10081158
34 Jang S.W. Hwang S.S. Kim H.S. Kim M.K. Lee W.H. Hwang S.U. Gwak J. Yew S.K. Flavell R.A. Lee G.R. Homeobox protein Hhex negatively regulates Treg cells by inhibiting Foxp3 expression and function Proc Natl Acad Sci U S A 116 51 2019 Dec 17 25790 25799 10.1073/pnas.1907224116 Epub 2019 Dec 2. PMID: 31792183; PMCID: PMC6926046 31792183
35 Xu Y. Melo-Cardenas J. Zhang Y. Gau I. Wei J. Montauti E. Zhang Y. Gao B. Jin H. Sun Z. Lee S.M. Fang D. The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine-induced ER stress response JCI Insight 4 5 2019 Mar 7 e121887 10.1172/jci.insight.121887 PMID: 30843874; PMCID: PMC6483511
36 Dong Y. Yang C. Pan F. Post-Translational regulations of Foxp3 in Treg cells and their therapeutic applications Front. Immunol. 12 2021 Apr 12 626172 10.3389/fimmu.2021.626172 PMID: 33912156; PMCID: PMC8071870
37 Le Menn G. Jabłońska A. Chen Z. The effects of post-translational modifications on Th17/Treg cell differentiation Biochim. Biophys. Acta Mol. Cell Res. 1869 6 2022 Jun 119223 10.1016/j.bbamcr.2022.119223 Epub 2022 Feb 1. PMID: 35120998
38 Peng X. Wang Q. Li W. Ge G. Peng J. Xu Y. Yang H. Bai J. Geng D. Comprehensive overview of microRNA function in rheumatoid arthritis Bone Res 11 1 2023 Jan 24 8 10.1038/s41413-023-00244-1 PMID: 36690624; PMCID: PMC9870909 36690624
39 Liu C. Li N. Liu G. The role of MicroRNAs in regulatory T cells J Immunol Res 2020 2020 Apr 2 3232061 10.1155/2020/3232061 PMID: 32322593; PMCID: PMC7154970
40 Zhang Y. Yang M. Xie H. Hong F. Yang S. Role of miRNAs in rheumatoid arthritis therapy Cells 12 13 2023 Jun 30 1749 10.3390/cells12131749 PMID: 37443783; PMCID: PMC10340706 37443783
41 Peng Q. Ratnasothy K. Boardman D.A. Jacob J. Tung S.L. McCluskey D. Smyth L.A. Lechler R.I. Dorling A. Lombardi G. Protease activated receptor 4 as a novel modulator of regulatory T cell function Front. Immunol. 10 2019 Jun 18 1311 10.3389/fimmu.2019.01311 PMID: 31275306; PMCID: PMC6591367 31275306
42 Du X. Shi H. Li J. Dong Y. Liang J. Ye J. Kong S. Zhang S. Zhong T. Yuan Z. Xu T. Zhuang Y. Zheng B. Geng J.G. Tao W. Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease J. Immunol. 192 4 2014 Feb 15 1525 1535 10.4049/jimmunol.1301060 Epub 2014 Jan 22. PMID: 24453252 24453252
43 Shen C.R. Yang W.C. Chen H.W. The fate of regulatory T cells: survival or apoptosis Cell. Mol. Immunol. 11 1 2014 Jan 11 13 10.1038/cmi.2013.49 Epub 2013 Nov 4. PMID: 24185711; PMCID: PMC4002139 24185711
44 Hu W. Wang Z.M. Feng Y. Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity Nat. Immunol. 22 2021 1163 1174 10.1038/s41590-021-01001-4 34426690
45 Cvetanovich G.L. Hafler D.A. Human regulatory T cells in autoimmune diseases Curr. Opin. Immunol. 22 6 2010 Dec 753 760 10.1016/j.coi.2010.08.012 Epub 2010 Sep 24. PMID: 20869862; PMCID: PMC2997859 20869862
46 Conrad N. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK Lancet 401 10391 2023 Jun 3 1878 1890 10.1016/S0140-6736(23)00457-9 Epub 2023 May 5. PMID: 37156255 37156255
47 Finckh A. Global epidemiology of rheumatoid arthritis Nat. Rev. Rheumatol. 18 10 2022 Oct 591 602 10.1038/s41584-022-00827-y Epub 2022 Sep 6. PMID: 36068354 36068354
48 Yan S. Kotschenreuther K. Deng S. Kofler D.M. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential Cell. Mol. Life Sci. 79 10 2022 Sep 29 533 10.1007/s00018-022-04563-0 PMID: 36173485; PMCID: PMC9522664 36173485
49 van Amelsfort J.M. Jacobs K.M. Bijlsma J.W. Lafeber F.P. Taams L.S. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid Arthritis Rheum. 50 9 2004 Sep 2775 2785 10.1002/art.20499 PMID: 15457445 15457445
50 Morita T. Shima Y. Wing J.B. Sakaguchi S. Ogata A. Kumanogoh A. The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis PLoS One 11 9 2016 Sep 13 e0162306 10.1371/journal.pone.0162306 PMID: 27622457; PMCID: PMC5021283
51 Valencia X. Stephens G. Goldbach-Mansky R. Wilson M. Shevach E.M. Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells Blood 108 1 2006 Jul 1 253 261 10.1182/blood-2005-11-4567 Epub 2006 Mar 14. PMID: 16537805; PMCID: PMC1895836 16537805
52 Nie H. Zheng Y. Li R. Guo T.B. He D. Fang L. Liu X. Xiao L. Chen X. Wan B. Chin Y.E. Zhang J.Z. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis Nat Med 19 3 2013 Mar 322 328 10.1038/nm.3085 Epub 2013 Feb 10. PMID: 23396208 23396208
53 Skrzypkowska M. Cytokines and chemokines multiplex analysis in patients with low disease activity rheumatoid arthritis Rheumatol. Int. 42 4 2022 Apr 609 619 10.1007/s00296-022-05103-6 Epub 2022 Feb 18. PMID: 35179632; PMCID: PMC8940835 35179632
54 Jiang Q. Yang G. Liu Q. Wang S. Cui D. Function and role of regulatory T cells in rheumatoid arthritis Front. Immunol. 12 2021 Apr 1 626193 10.3389/fimmu.2021.626193 PMID: 33868244; PMCID: PMC8047316
55 van Amelsfort J.M. van Roon J.A. Noordegraaf M. Jacobs K.M. Bijlsma J.W. Lafeber F.P. Taams L.S. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis Arthritis Rheum. 56 3 2007 Mar 732 742 10.1002/art.22414 PMID: 17328044 17328044
56 Chakraborty S. Gupta R. Kubatzky K.F. Kar S. Kraus F.V. Souto-Carneiro M.M. Lorenz H.M. Kumar P. Kumar V. Mitra D.K. Negative impact of Interleukin-9 on synovial regulatory T cells in rheumatoid arthritis Clin Immunol 257 2023 Dec 109814 10.1016/j.clim.2023.109814 Epub 2023 Oct 23. PMID: 37879380
57 Corthay A. How do regulatory T cells work? Scand. J. Immunol. 70 4 2009 Oct 326 336 10.1111/j.1365-3083.2009.02308.x PMID: 19751267; PMCID: PMC2784904 19751267
58 Li Y.S. Luo W. Zhu S.A. Lei G.H. T cells in osteoarthritis: alterations and beyond Front. Immunol. 8 2017 Mar 30 356 10.3389/fimmu.2017.00356 PMID: 28424692; PMCID: PMC5371609 28424692
59 Moradi B. CD4⁺CD25⁺/highCD127low/⁻ regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints--analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood Arthritis Res. Ther. 16 2 2014 Apr 17 R97 10.1186/ar4545 PMID: 24742142; PMCID: PMC4060198
60 Xia N. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction Circulation 142 20 2020 Nov 17 1956 1973 10.1161/CIRCULATIONAHA.120.046789 Epub 2020 Sep 28. PMID: 32985264 32985264
61 Wang H.Y. Ye J.R. Cui L.Y. Chu S.F. Chen N.H. Regulatory T cells in ischemic stroke Acta Pharmacol. Sin. 43 1 2022 Jan 1 9 10.1038/s41401-021-00641-4 Epub 2021 Mar 26. PMID: 33772140; PMCID: PMC8724273 33772140
62 Shi L. Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke Immunity 54 7 2021 Jul 13 1527 1542.e8 10.1016/j.immuni.2021.04.022 Epub 2021 May 19. PMID: 34015256; PMCID: PMC8282725 34015256
63 Das S. Rai G. Sood V. Singh P.K. Tyagi A. Salhotra R. Gupta C. Jaggi V.K. Dar S.A. Ansari M.A. Incompetent memory immune response in severe COVID-19 patients under treatment Heliyon 9 10 2023 Sep 30 e20590 10.1016/j.heliyon.2023.e20590 PMID: 37817995; PMCID: PMC10560768
64 Togashi Y. Shitara K. Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy Nat. Rev. Clin. Oncol. 16 6 2019 Jun 356 371 10.1038/s41571-019-0175-7 PMID: 30705439 30705439
65 Verma A. Mathur R. Farooque A. Kaul V. Gupta S. Dwarakanath B.S. T-regulatory cells in tumor progression and therapy Cancer Manag. Res. 11 2019 Dec 24 10731 10747 10.2147/CMAR.S228887 PMID: 31920383; PMCID: PMC6935360 31920383
66 Dwivedi M. Tiwari S. Kemp E.H. Begum R. Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics Heliyon 8 8 2022 Aug 27 e10450 10.1016/j.heliyon.2022.e10450 PMID: 36082331; PMCID: PMC9445387
67 Lykhopiy V. Malviya V. Humblet-Baron S. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity Genes Immun 24 2023 248 262 10.1038/s41435-023-00221-y 37741949
68 Gliwiński M. Iwaszkiewicz-Grześ D. Trzonkowski P. Cell-based therapies with T regulatory cells BioDrugs 31 4 2017 Aug 335 347 10.1007/s40259-017-0228-3 PMID: 28540499; PMCID: PMC5548816 28540499
69 Giganti G. Atif M. Mohseni Y. Mastronicola D. Grageda N. Povoleri G.A. Miyara M. Scottà C. Treg cell therapy: how cell heterogeneity can make the difference Eur. J. Immunol. 51 1 2021 Jan 39 55 10.1002/eji.201948131 Epub 2020 Dec 23. PMID: 33275279 33275279
70 Gu J. Shao Q. Zhou J. Chen Q. Lu L. Protocol for in vitro isolation, induction, expansion, and determination of human natural regulatory T cells and induced regulatory T cells STAR Protoc 3 4 2022 Dec 16 101740 10.1016/j.xpro.2022.101740 Epub 2022 Oct 9. PMID: 36219560; PMCID: PMC9563191
71 Trzonkowski P. Hurdles in therapy with regulatory T cells Sci. Transl. Med. 7 304 2015 Sep 9 304ps18 10.1126/scitranslmed.aaa7721 PMID: 26355029
72 Fuchs A. Minimum information about T regulatory cells: a step toward reproducibility and standardization Front. Immunol. 8 2018 Jan 15 1844 10.3389/fimmu.2017.01844 PMID: 29379498; PMCID: PMC5775516 29379498
73 Abhishek K. Nidhi M. Chandran S. Shevkoplyas S.S. Mohan C. Manufacturing regulatory T cells for adoptive cell therapy in immune diseases: a critical appraisal Clin Immunol 251 2023 Jun 109328 10.1016/j.clim.2023.109328 Epub 2023 Apr 20. PMID: 37086957
74 Reinhardt J. Sharma V. Stavridou A. Lindner A. Reinhardt S. Petzold A. Lesche M. Rost F. Bonifacio E. Eugster A. Distinguishing activated T regulatory cell and T conventional cells by single-cell technologies Immunology 166 1 2022 May 121 137 10.1111/imm.13460 Epub 2022 Mar 2. PMID: 35196398; PMCID: PMC9426617 35196398
75 Balcerek J. Shy B.R. Putnam A.L. Masiello L.M. Lares A. Dekovic F. Acevedo L. Lee M.R. Nguyen V. Liu W. Paruthiyil S. Xu J. Leinbach A.S. Bluestone J.A. Tang Q. Esensten J.H. Polyclonal regulatory T cell manufacturing under cGMP: a decade of experience Front. Immunol. 12 2021 Nov 18 744763 10.3389/fimmu.2021.744763 PMID: 34867967; PMCID: PMC8636860
76 Skartsis N. Peng Y. Ferreira L.M.R. Nguyen V. Ronin E. Muller Y.D. Vincenti F. Tang Q. IL-6 and TNFα drive extensive proliferation of human Tregs without compromising their lineage stability or function Front. Immunol. 12 2021 Dec 23 783282 10.3389/fimmu.2021.783282 PMID: 35003100; PMCID: PMC8732758
77 Someya K. Nakatsukasa H. Ito M. Kondo T. Tateda K.I. Akanuma T. Koya I. Sanosaka T. Kohyama J. Tsukada Y.I. Takamura-Enya T. Yoshimura A. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation Int. Immunol. 29 8 2017 Aug 1 365 375 10.1093/intimm/dxx049 PMID: 29048538; PMCID: PMC5890887 29048538
78 Thangavelu G. Andrejeva G. Bolivar-Wagers S. Retinoic acid signaling acts as a rheostat to balance Treg function Cell. Mol. Immunol. 19 2022 820 833 10.1038/s41423-022-00869-y 35581350
79 Dawson N.A.J. Levings M.K. Antigen-specific regulatory T cells: are police CARs the answer? Transl. Res. 187 2017 Sep 53 58 10.1016/j.trsl.2017.06.009 Epub 2017 Jun 19. PMID: 28688236 28688236
80 Brunstein C.G. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Blood 117 3 2011 Jan 20 1061 1070 10.1182/blood-2010-07-293795 Epub 2010 Oct 15. PMID: 20952687; PMCID: PMC3035067 20952687
81 Wang C. Wang J. Che S. Zhao H. CAR-T cell therapy for hematological malignancies: history, status and promise Heliyon 9 11 2023 Nov 7 e21776 10.1016/j.heliyon.2023.e21776 PMID: 38027932; PMCID: PMC10658259
82 Amini L. Greig J. Schmueck-Henneresse M. Volk H.D. Bézie S. Reinke P. Guillonneau C. Wagner D.L. Anegon I. Super-treg: toward a new era of adoptive Treg therapy enabled by genetic modifications Front. Immunol. 11 2021 Feb 24 611638 10.3389/fimmu.2020.611638 PMID: 33717052; PMCID: PMC7945682
83 McCallion O. Bilici M. Hester J. Issa F. Regulatory T-cell therapy approaches Clin. Exp. Immunol. 211 2 2023 Mar 16 96 107 10.1093/cei/uxac078 PMID: 35960852; PMCID: PMC10019137 35960852
84 Sterner R.C. Sterner R.M. CAR-T cell therapy: current limitations and potential strategies Blood Cancer J. 11 4 2021 Apr 6 69 10.1038/s41408-021-00459-7 PMID: 33824268; PMCID: PMC8024391 33824268
85 Stucchi A. Maspes F. Montee-Rodrigues E. Fousteri G. Engineered Treg cells: the heir to the throne of immunotherapy J. Autoimmun. 144 2024 Apr 102986 10.1016/j.jaut.2022.102986 Epub 2023 Jan 11. PMID: 36639301
86 Ajeganova S. Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations Ther Adv Musculoskelet Dis 9 10 2017 Oct 249 262 10.1177/1759720X17720366 Epub 2017 Aug 2. PMID: 28974987; PMCID: PMC5613855 28974987
87 Gao Y. Gao Y.N. Wang M.J. Zhang Y. Zhang F.Q. He Z.X. Chen W. Li H.C. Xie Z.J. Wen C.P. Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis Heliyon 9 5 2023 Apr 28 e15839 10.1016/j.heliyon.2023.e15839 PMID: 37215854; PMCID: PMC10196519
88 Zhu H. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study Clin. Rheumatol. 37 3 2018 Mar 597 605 10.1007/s10067-017-3850-z Epub 2017 Nov 7. PMID: 29116543 29116543
89 Hartemann A. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol. 1 4 2013 Dec 295 305 10.1016/S2213-8587(13)70113-X Epub 2013 Oct 8. PMID: 24622415 24622415
90 von Spee-Mayer C. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus Ann. Rheum. Dis. 75 7 2016 Jul 1407 1415 10.1136/annrheumdis-2015-207776 Epub 2015 Aug 31. PMID: 26324847 26324847
91 Zheng X. Su R. Hu F. Liu Y. Li X. Gao C. Wang C. Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viremia Autoimmun. Rev. 21 11 2022 Nov 103186 10.1016/j.autrev.2022.103186 Epub 2022 Sep 7. PMID: 36084894
92 ClinicalTrials.gov [Internet] National Library of Medicine (US). 8600 Rockville Pike 2000 Feb 29 Identifier NCT06201416, Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis; 2024 March 6; [about 4 screens]. Available from:
93 Rosenzwajg M. Lorenzon R. Cacoub P. Pham H.P. Pitoiset F. El Soufi K. Ribet C. Bernard C. Aractingi S. Banneville B. Beaugerie L. Berenbaum F. Champey J. Chazouilleres O. Corpechot C. Fautrel B. Mekinian A. Regnier E. Saadoun D. Salem J.E. Sellam J. Seksik P. Daguenel-Nguyen A. Doppler V. Mariau J. Vicaut E. Klatzmann D. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial Ann. Rheum. Dis. 78 2 2019 Feb 209 217 10.1136/annrheumdis-2018-214229 Epub 2018 Nov 24. PMID: 30472651 30472651
94 [a] Lorenzon R. Ribet C. Pitoiset F. Aractingi S. Banneville B. Beaugerie L. Berenbaum F. Cacoub P. Champey J. Chazouilleres O. Corpechot C. Fautrel B. Mekinian A. Regnier E. Saadoun D. Salem J.E. Sellam J. Seksik P. Vicaut E. Rosenzwajg M. Klatzmann D. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial J. Autoimmun. 144 2024 Apr 103172 10.1016/j.jaut.2024.103172 Epub 2024 Feb 7. PMID: 38330545
[b] Wu R. Li N. Zhao X. Ding T. Xue H. Gao C. Li X. Wang C. Low-dose Interleukin-2: biology and therapeutic prospects in rheumatoid arthritis Autoimmun. Rev. 19 10 2020 Oct 102645 10.1016/j.autrev.2020.102645 Epub 2020 Aug 13. PMID: 32801037
95 Carvajal Alegria G. Cornec D. Saraux A. Devauchelle-Pensec V. Jamin C. Hillion S. Pers J.O. Pochard P. Abatacept promotes regulatory B cell functions, enhancing their ability to reduce the Th1 response in rheumatoid arthritis patients through the production of IL-10 and TGF-β J. Immunol. 207 2 2021 Jul 15 470 482 10.4049/jimmunol.2000455 Epub 2021 Jul 9. PMID: 34244295 34244295
96 Zhang X. Miao M. Zhang R. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial Sig Transduct Target Ther 7 2022 67 10.1038/s41392-022-00887-2
97 Ghoryani M. Shariati-Sarabi Z. Tavakkol-Afshari J. Ghasemi A. Poursamimi J. Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran Biomed. Pharmacother. 109 2019 Jan 1834 1840 10.1016/j.biopha.2018.11.056 Epub 2018 Nov 26. PMID: 30551438 30551438
98 Rahimi Khorashad M. Ghoryani M. Gowhari Shabgah A. Shariati-Sarabi Z. Tavakkol Afshari J. Mohammadi M. The effects of mesenchymal stem cells on the gene expression of TGF-beta and IFN-gamma in patients with rheumatoid arthritis Iran. J. Allergy, Asthma Immunol. 22 2 2023 Apr 30 183 189 10.18502/ijaai.v22i2.12679 PMID: 37496411 37496411
99 Alavi M. Tavakkol-Afshari J. Shariati-Sarabi Z. Shabgah A.G. Ghoryani M. Ghasemi A. Mohammadi M. Intravenous injection of autologous bone marrow-derived mesenchymal stem cells on the gene expression and plasma level of CCL5 in refractory rheumatoid arthritis J. Res. Med. Sci. 25 2020 Dec 30 111 10.4103/jrms.JRMS_308_20 PMID: 33912221; PMCID: PMC8067892 33912221
100 El-Banna H.S. Gado S.E. Vitamin D: does it help Tregs in active rheumatoid arthritis patients Expert Rev Clin Immunol. 16 8 2020 Aug 847 853 10.1080/1744666X.2020.1805317 Epub 2020 Aug 25. PMID: 32783547 32783547
101 Trzonkowski P. Bieniaszewska M. Juścińska J. Dobyszuk A. Krzystyniak A. Marek N. Myśliwska J. Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells Clin Immunol 133 1 2009 Oct 22 26 10.1016/j.clim.2009.06.001 Epub 2009 Jun 25. PMID: 19559653 19559653
102 Marek-Trzonkowska N. Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children Diabetes Care 35 9 2012 Sep 1817 1820 10.2337/dc12-0038 Epub 2012 Jun 20. PMID: 22723342; PMCID: PMC3425004 22723342
103 Chwojnicki K. Administration of CD4+CD25highCD127-FoxP3+ regulatory T cells for relapsing-remitting multiple sclerosis: a phase 1 study BioDrugs 35 1 2021 Jan 47 60 10.1007/s40259-020-00462-7 Epub 2021 Jan 5. PMID: 33400237 33400237
104 Martinec R. Pinjatela R. Balen D. Quality of life in patients with rheumatoid arthritis - a preliminary study Acta Clin. Croat. 58 1 2019 Mar 157 166 10.20471/acc.2019.58.01.20 PMID: 31363338; PMCID: PMC6629210 31363338
105 Cribbs A.P. Kennedy A. Penn H. Read J.E. Amjadi P. Green P. Syed K. Manka S.W. Brennan F.M. Gregory B. Williams R.O. Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway Arthritis Rheumatol. 66 9 2014 Sep 2344 2354 10.1002/art.38715 PMID: 24891289 24891289
106 Marek N. Bieniaszewska M. Krzystyniak A. Juścińska J. Myśliwska J. Witkowski P. Hellmann A. Trzonkowski P. The time is crucial for ex vivo expansion of T regulatory cells for therapy Cell Transplant. 20 11–12 2011 1747 1758 10.3727/096368911X566217 Epub 2011 Apr 1. PMID: 21457615 21457615
107 Marek-Trzonkowska N. Piekarska K. Filipowicz N. Piotrowski A. Gucwa M. Vogt K. Sawitzki B. Siebert J. Trzonkowski P. Mild hypothermia provides Treg stability Sci. Rep. 7 1 2017 Sep 20 11915 10.1038/s41598-017-10151-1 Erratum in: Sci Rep. 2017 Dec 15;7(1):17940. PMID: 28931834; PMCID: PMC5607276
108 Álvaro-Gracia J.M. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial Ann. Rheum. Dis. 76 1 2017 Jan 196 202 10.1136/annrheumdis-2015-208918 Epub 2016 Jun 7. PMID: 27269294 27269294
109 Harna B. Mesenchymal stromal cell therapy for patients with rheumatoid arthritis Exp. Cell Res. 423 1 2023 Feb 1 113468 10.1016/j.yexcr.2023.113468 Epub 2023 Jan 5. PMID: 36621669
110 Lalu M.M. McIntyre L. Pugliese C. Fergusson D. Winston B.W. Marshall J.C. Granton J. Stewart D.J. Canadian Critical Care Trials Group Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials PLoS One 7 10 2012 e47559 10.1371/journal.pone.0047559 Epub 2012 Oct 25. PMID: 23133515; PMCID: PMC3485008
111 Piekarska K. Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity Nat. Commun. 13 1 2022 Feb 14 856 10.1038/s41467-022-28338-0 PMID: 35165293; PMCID: PMC8844425 35165293
112 Kurtzberg J. Laughlin M. Graham M.L. Smith C. Olson J.F. Halperin E.C. Ciocci G. Carrier C. Stevens C.E. Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients N. Engl. J. Med. 335 3 1996 Jul 18 157 166 10.1056/NEJM199607183350303 PMID: 8657213 8657213
113 Barker J.N. Davies S.M. DeFor T. Ramsay N.K. Weisdorf D.J. Wagner J.E. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis Blood 97 10 2001 May 15 2957 2961 10.1182/blood.v97.10.2957 PMID: 11342417 11342417
114 Wang Q. Wang Y. Chang C. Ma F. Peng D. Yang S. An Y. Deng Q. Wang Q. Gao F. Wang F. Tang H. Qi X. Jiang X. Cai D. Zhou G. Comparative analysis of mesenchymal stem/stromal cells derived from human induced pluripotent stem cells and the cognate umbilical cord mesenchymal stem/stromal cells Heliyon 9 1 2023 Jan 4 e12683 10.1016/j.heliyon.2022.e12683 PMID: 36647346; PMCID: PMC9840238
115 Gladstone D.E. Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS Blood Adv 7 13 2023 Jul 11 3075 3079 10.1182/bloodadvances.2022009619 PMID: 36961352; PMCID: PMC10043947 36961352
116 Ballen K. Umbilical cord blood transplantation: challenges and future directions Stem Cells Transl Med 6 5 2017 May 1312 1315 10.1002/sctm.17-0069 PMID: 28456009; PMCID: PMC5442719 28456009
117 Pakzad M. A roadmap for the production of a GMP-compatible cell bank of allogeneic bone marrow-derived clonal mesenchymal stromal cells for cell therapy applications Stem Cell Rev Rep 18 7 2022 Oct 2279 2295 10.1007/s12015-022-10351-x Epub 2022 Feb 17. PMID: 35175538; PMCID: PMC8852915 35175538
118 Caldwell K.J. Gottschalk S. Talleur A.C. Allogeneic CAR cell therapy-more than a pipe dream Front. Immunol. 11 2021 Jan 8 618427 10.3389/fimmu.2020.618427 PMID: 33488631; PMCID: PMC7821739
119 Johansen K.H. How CRISPR/Cas9 gene editing is revolutionizing T cell research DNA Cell Biol. 41 1 2022 Jan 53 57 10.1089/dna.2021.0579 Epub 2021 Dec 22. PMID: 34939826; PMCID: PMC8787706 34939826
